An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

NCT02581631 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Disease

Interventions

BIOLOGICAL: Nivolumab
DRUG: Brentuximab Vedotin

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]